PUBLICATIONS CeRePP & Etude PROGENE

Hôpital Tenon

Informations

• Publié par: Nisig
• Nombre de lectures: 35
• Langue: English

Extrait

PUBLICATIONS CeRePP & Etude PROGENE Recherches sur le diagnostic précoce du cancer de la prostate : 1. AzzouziAR, Larre S, Cormier L, Roupret M, Valeri A, Mangin P, Berthon P, Villette JM, Fiet J, Cussenot O. Relevance of the prostatespecific antigen (PSA) nanotest compared to the classical PSA test in the organized mass screening of prostate cancer. BJU Int. 2007 Apr;99(4):7624. 2. CormierL, Guillemin F, Valeri A, Fournier G, Cussenot O, Mangin P, Litwin MS. Impact of prostate cancer screening on healthrelated quality of life in atrisk families. Urology. 2002 Jun;59(6):9016. 3. RoumierX, Azzouzi R, Valeri A, Guillemin F, Fournier G, Cussenot O, Mangin P, Cormier L. Adherence to an annual PSA screening program over 3 years for brothers and sons of men with prostate cancer. Eur Urol. 2004 Mar;45(3):2805; 4. RoupretM, Fromont G, Bitker MO, Gattegno B, Vallancien G, Cussenot O. Outcome after radical prostatectomy in young men with or without a family history of prostate cancer. Urology. 2006 May;67(5):102832. 5. ValeriA, Briollais L, Azzouzi R, Fournier G, Mangin P, Berthon P, Cussenot O, Demenais F. Segregation analysis of prostate cancer in France: evidence for autosomal dominant inheritance and residual brotherbrother dependence. Ann Hum Genet. 2003 Mar;67(Pt 2):12537. 6. ValeriA, Cormier L, Moineau MP, CancelTassin G, Azzouzi R, Doucet L, Baschet F, Cussenot I, L'Her J, Berthon P, Mangin P, Cussenot O, Morin JF, Fournier G. Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives. J Urol. 2002 Aug;168(2):4837. 7. ValeriA, Fournier G, Morin V, Morin JF, Drelon E, Mangin P, Teillac P, Berthon P, Cussenot O. Early onset and familial predisposition to prostate cancer significantly enhance the probability for breast cancer in first degree relatives. Int J Cancer 2000; 86:8837. Recherches sur les gènes de prédisposition au cancer de la prostate : 8. BerthonP, Valeri A, CohenAkenine A, Drelon E, Paiss T, Wohr G, Latil A, Millasseau P, Mellah I, Cohen N, Blanche H, BellaneChantelot C, Demenais F, Teillac P, Le Duc A, de Petriconi R, Hautmann R, Chumakov I, Bachner L, Maitland NJ, Lidereau R, Vogel W, Fournier G, Mangin P, Cussenot OPredisposing gene for earlyonset prostate cancer, localized on chromosome 1q42.243. Am J Hum Genet. 1998 Jun;62(6):141624. 9. AzzouziAR, StoppaLyonnet D, Roupret M, Larre S, Mangin P, Cussenot O. BRCA2 mutation screening is clinically relevant in breast and early prostate cancer families. Int J Urol. 2007 May;14(5):4456. 10. AzzouziAR, CochandPriollet B, Mangin P, Fournier G, Berthon P, Latil A, Cussenot O. Impact of constitutional genetic variation in androgen/oestrogenregulating genes on age related changes in human prostate. Eur J Endocrinol. 2002 Oct;147(4):47984. 11. CancelTassinG, Latil A, Rousseau F, Mangin P, Bottius E, Escary JL, Berthon P, Cussenot O. Association study of polymorphisms in the human estrogen receptor alpha gene and prostate cancer risk. Eur Urol. 2003 Oct;44(4):48790. 12. CancelTassin G, Latil A, Valeri A, Mangin P, Fournier G, Berthon P, Cussenot O. PCAP is the major known prostate cancer predisposing locus in families from south and west Europe. Eur J Hum Genet. 2001 Feb;9(2):13542 13. CorreaCerroL, Berthon P, Haussler J, Bochum S, Drelon E, Mangin P, Fournier G, Paiss T, Cussenot O, Vogel W. Vitamin D receptor polymorphisms as markers in prostate cancer.Hum Genet. 1999 Sep;105(3):2817.

14. CorreaCerroL, Wohr G, Haussler J, Berthon P, Drelon E, Mangin P, Fournier G, Cussenot O, Kraus P, Just W, Paiss T, Cantu JM, Vogel W. (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a FrenchGerman population. Eur J Hum Genet. 1999 Apr;7(3):35762 15. CussenotO, Azzouzi AR, Nicolaiew N, Fromont G, Mangin P, Cormier L, Fournier G, Valeri A, Larre S, Thibault F, Giordanella JP, Pouchard M, Zheng Y, Hamdy FC, Cox A, CancelTassin G. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J Clin Oncol. 2007 Aug 20;25(24):3596602. 16. CussenotO, Azzouzi AR, Nicolaiew N, Mangin P, Cormier L, Fournier G, Valeri A, CancelTassin G.Lowactivity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5alphareductase inhibitors. Eur Urol. 2007 Oct;52(4):10827. 17. Latil AG, Azzouzi R, Cancel GS, Guillaume EC, CochanPriollet B, Berthon PL, Cussenot O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer. 2001 Sep 1;92(5):11307. 18. YeagerM, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, CancelTassin G, Cussenot O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hunter DJ, Chanock SJ, Thomas G.Genomewide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007 May;39(5):6459. 19. LarreS, Hamadeh H, Azzouzi AR, Vallancien G, CochandPriollet B, CancelTassin G, Cussenot O. Genetic impact on prostate anatomical variability during ageing: role of CYP17, SRD5A2 and androgen receptor genes polymorphisms. BJU Int. 2007 Sep;100(3):67984. Recherches sur les marqueurs moléculaires associés à cancers de la prostate agressifs 20. RoupretM, Hupertan V, Yates DR, Catto JW, Rehman I, Meuth M, Ricci S, Lacave R, CancelTassin G, de la Taille A, Rozet F, Cathelineau X, Vallancien G, Hamdy FC, Cussenot O. Molecular detection of localized prostate cancer using quantitative methylationspecific PCR on urinary cells obtained following prostate massage. Clin Cancer Res. 2007 Mar 15;13(6):17205. 21. ThuretR, ChantrelGroussard K, Azzouzi AR, Villette JM, Guimard S, Teillac P, Berthon P, Houlgatte A, Latil A, Cussenot O.Clinical relevance of genetic instability in prostatic cells obtained by prostatic massage in early prostate cancer. Br J Cancer. 2005 Jan 31;92(2):23640. 22. FromontG, Vallancien G, Validire P, Levillain P, Cussenot O. BCAR1 expression in prostate cancer: association with 16q23 LOH status, tumor progression and EGFR/KAI1 staining. Prostate. 2007 Feb 15;67(3):26873. 23. Fromont G, Joulin V, ChantrelGroussard K, Vallancien G, Guillonneau B, Validire P, Latil A, Cussenot O. Allelic losses in localized prostate cancer: association with prognostic factors. J Urol. 2003 Oct;170(4 Pt 1):13947. 24. LatilA, Chene L, Mangin P, Fournier G, Berthon P, Cussenot O. Extensive analysis of the 13q14 region in human prostate tumors: DNA analysis and quantitative expression of genes lying in the interval of deletion. Prostate. 2003 Sep 15;57(1):3950. 25. FromontG, Chene L, Vidaud M, Vallancien G, Mangin P, Fournier G, Validire P, Latil A, Cussenot O. Differential expression of 37 selected genes in hormonerefractory prostate cancer using quantitative taqman realtime RTPCR. Int J Cancer. 2005 Mar 20;114(2):17481.